Citadel Advisors
MREO

Citadel Advisors’s Mereo BioPharma MREO Stock Holding History

Citadel Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Buy
387,000
+255,500
+194% +$110K ﹤0.01% 11822
2025
Q4 		$54.8K Buy
131,500
+105,800
+412% +$201K ﹤0.01% 11995
2025
Q3 		$52.9K Sell
25,700
-36,500
-59% -$67.3K ﹤0.01% 12168
2025
Q2 		$169K Sell
62,200
-14,300
-19% -$34.5K ﹤0.01% 10846
2025
Q1 		$172K Sell
76,500
-7,400
-9% -$20.9K ﹤0.01% 10660
2024
Q4 		$294K Buy
83,900
+67,200
+402% +$264K ﹤0.01% 9698
2024
Q3 		$68.6K Sell
16,700
-11,200
-40% -$46.3K ﹤0.01% 11586
2024
Q2 		$100K Sell
27,900
-5,100
-15% -$16.5K ﹤0.01% 10917
2024
Q1 		$109K Buy
33,000
+23,300
+240% +$78.9K ﹤0.01% 11237
2023
Q4 		$22.4K Buy
9,700
+4,700
+94% +$8.99K ﹤0.01% 12525
2023
Q3 		$6.45K Buy
5,000
+4,600
+1,150% +$6.1K ﹤0.01% 13318
2023
Q2 		$528 Sell
400
-600
-60% -$696 ﹤0.01% 14094
2023
Q1 		$707 Sell
1,000
-91,900
-99% -$82.7K ﹤0.01% 14431
2022
Q4 		$69.7K Sell
92,900
-6,700
-7% -$5.5K ﹤0.01% 11708
2022
Q3 		$86K Sell
99,600
-48,800
-33% -$59.7K ﹤0.01% 11220
2022
Q2 		$166K Buy
148,400
+132,600
+839% +$103K ﹤0.01% 10877
2022
Q1 		$18K Buy
15,800
+300
+2% +$388 ﹤0.01% 13274
2021
Q4 		$25K Sell
15,500
-22,200
-59% -$44.4K ﹤0.01% 13533
2021
Q3 		$91K Sell
37,700
-25,300
-40% -$67K ﹤0.01% 12967
2021
Q2 		$200K Sell
63,000
-5,900
-9% -$19.8K ﹤0.01% 12163
2021
Q1 		$232K Buy
+68,900
New +$244K ﹤0.01% 11417

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citadel Advisors's MREO Position: Q4 2025 in Review

Citadel Advisors sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 3,171,632 shares — an estimated $6.04M sold.

Citadel Advisors first reported a position in MREO in Q3 2020 and held it in 21 quarters. The position peaked at $14.7M in Q4 2020. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Citadel Advisors reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 3,171,632 Mereo BioPharma shares in Q4 2025, an estimated $6.04M.
  • Citadel Advisors first reported a position in Mereo BioPharma in Q3 2020 and held it in 21 quarters.
  • Citadel Advisors's Mereo BioPharma position peaked at $14.7M in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.